Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangiti

 – First and Only Treatment to Demonstrate Statistically Significant Reductions Across Key Biomarkers, ALP Normalization and Pruritus Versus Placebo –

https://www.businesswire.com/news/home/20240814469557/en